Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements

Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009

(2012) A Sita-Lumsden et al.   BRITISH JOURNAL OF CANCER

EMA/CO for High-Risk Gestational Trophoblastic Neoplasia: Good Outcomes With Induction Low-Dose Etoposide-Cisplatin and Genetic Analysis

(2012) Constantine Alifrangis et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study

(2011) Raymond J. Osborne et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias

(2010) B. You et al.   ANNALS OF ONCOLOGY

Gestational trophoblastic disease

(2010) Michael J Seckl et al.   LANCET

Handling Data Below the Limit of Quantification in Mixed Effect Models

(2009) Martin Bergstrand et al.   AAPS Journal

Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity

(2009) Gihad Elias Chalouhi et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease

(2009) L G Kerkmeijer et al.   BRITISH JOURNAL OF CANCER

Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia

(2008) Whitfield B. Growdon et al.   GYNECOLOGIC ONCOLOGY

Likelihood based approaches to handling data below the quantification limit using NONMEM VI

(2008) Jae Eun Ahn et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS